Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Meignier

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
International Journal of Cancer|September 15, 1986
Failure to induce cervical cancer in mice by long-term frequent vaginal exposure to live or inactivated herpes simplex virusesB Meignier, B Norrild, C Thuning, et al.
Journal of Virology|November 1, 1996
Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strainM Girard, L Yue, F Barré-Sinoussi, et al.
International Journal of Cancer|September 15, 1986
Analyses of transplanted murine tumors for HSV DNA sequencesF Yehiely, C Thuning, B Meignier, et al.
AIDS Research and Human Retroviruses|December 9, 1997
Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccinesE Coëffier, J L Excler, M P Kieny, et al.
Developments in Biological Standardization|January 1, 1995
The safety and use of canarypox vectored vaccinesS A Plotkin, M Cadoz, B Meignier, et al.
Journal of Virology|October 1, 1995
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1M Girard, B Meignier, F Barré-Sinoussi, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 1, 1994
Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted virusesK Berencsi, A Uri, T Valyi-Nagy, et al.
AIDS (London, England)|April 1, 1996
Antiplatelet antibodies during the course of HIV-preventive vaccine trialC Kaplan, M C Morel-Kopp, M P Kieny, et al.
AIDS Research and Human Retroviruses|March 1, 1995
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDAG Pialoux, J L Excler, Y Rivière, et al.
AIDS Research and Human Retroviruses|December 1, 1995
Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteersD Salmon-Céron, J L Excler, D Sicard, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
International Journal of Cancer|September 15, 1986
Failure to induce cervical cancer in mice by long-term frequent vaginal exposure to live or inactivated herpes simplex virusesB Meignier, B Norrild, C Thuning, et al.
Journal of Virology|November 1, 1996
Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strainM Girard, L Yue, F Barré-Sinoussi, et al.
International Journal of Cancer|September 15, 1986
Analyses of transplanted murine tumors for HSV DNA sequencesF Yehiely, C Thuning, B Meignier, et al.
AIDS Research and Human Retroviruses|December 9, 1997
Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccinesE Coëffier, J L Excler, M P Kieny, et al.
Developments in Biological Standardization|January 1, 1995
The safety and use of canarypox vectored vaccinesS A Plotkin, M Cadoz, B Meignier, et al.
Journal of Virology|October 1, 1995
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1M Girard, B Meignier, F Barré-Sinoussi, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|September 1, 1994
Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted virusesK Berencsi, A Uri, T Valyi-Nagy, et al.
AIDS (London, England)|April 1, 1996
Antiplatelet antibodies during the course of HIV-preventive vaccine trialC Kaplan, M C Morel-Kopp, M P Kieny, et al.
AIDS Research and Human Retroviruses|March 1, 1995
A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDAG Pialoux, J L Excler, Y Rivière, et al.
AIDS Research and Human Retroviruses|December 1, 1995
Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteersD Salmon-Céron, J L Excler, D Sicard, et al.
Pageof 5